Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: Circ0120816 acts as an oncogene of esophageal squamous cell carcinoma by inhibiting miR-1305 and releasing TXNRD1

Fig. 7

MiR-1305 suppressed ESCC progression by targeting TXNRD1. a RT-qPCR analysis of the expression of TXNRD1 after transfecting with TXNRD1 siRNA and/or miR-1305 inhibitor. b CCK-8 assay was performed to evaluate the cell viability of ESCC cells after transfection. c BrdU assay was conducted to evaluate the proliferation of ESCC cell lines after transfection. d Cell adhesion assay was used to assess the adhesion ability of ESCC cell lines after transfection. e Cell cycle assay was applied to evaluate the cell cycle in ESCC cell lines after transfecting with a flow cytometry system. f The expression of cyclinB1, ICAM1 and VCAM1 was detected in ESCC cell lines after transfecting with western blot assay. g Caspase 3 activity assay indicates the cell apoptosis of ESCC cell lines after transfection. h The expression of Cleaved PARP, Bax and Cleaved Caspase-3 was detected in ESCC cell lines after transfecting with western blot assay. *P < 0.05, **P < 0.001, compared with the blank control group. #P < 0.05, ##P < 0.001, compared with the co-transfection group of si-TXNRD1 plus miR-1305 inhibitor. CON: blank control, NC: negative control, inhibitor: miR-1305 inhibitor, si: TXNRD1 siRNA, si + inhibitor: TXNRD1 siRNA plus miR-1305 inhibitor. Each experiment was independently repeated three times, and the data collected were displayed in the format of mean ± standard deviation (SD)

Back to article page